CUP0 Stock Overview
Engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for CUP0 from our risk checks.
Chugai Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥21.40 |
| 52 Week High | JP¥21.80 |
| 52 Week Low | JP¥18.00 |
| Beta | 0.54 |
| 11 Month Change | -1.83% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 18.23% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| CUP0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 3.9% | 3.1% | 4.5% |
| 1Y | n/a | -12.1% | 13.4% |
Return vs Industry: Insufficient data to determine how CUP0 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how CUP0 performed against the German Market.
Price Volatility
| CUP0 volatility | |
|---|---|
| CUP0 Average Weekly Movement | 4.8% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CUP0 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CUP0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1925 | 7,604 | Osamu Okuda | www.chugai-pharm.co.jp |
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases.
Chugai Pharmaceutical Co., Ltd. Fundamentals Summary
| CUP0 fundamental statistics | |
|---|---|
| Market cap | €76.06b |
| Earnings (TTM) | €2.24b |
| Revenue (TTM) | €6.83b |
34.0x
P/E Ratio11.1x
P/S RatioIs CUP0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CUP0 income statement (TTM) | |
|---|---|
| Revenue | JP¥1.08t |
| Cost of Revenue | JP¥331.21b |
| Gross Profit | JP¥753.36b |
| Other Expenses | JP¥398.32b |
| Earnings | JP¥355.04b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 25, 2024
| Earnings per share (EPS) | 215.77 |
| Gross Margin | 69.46% |
| Net Profit Margin | 32.74% |
| Debt/Equity Ratio | 0% |
How did CUP0 perform over the long term?
See historical performance and comparison